Continue Reading
Full article on Unknown
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
Market Intelligence Analysis
AI-Powered
Why This Matters
MediciNova announced an update on its Phase 2b/3 clinical trial of MN-166 (ibudilast) in ALS, presenting patient basic characteristics data at the 36th International Symposium on ALS/MND.
Market Impact
Market impact analysis based on neutral sentiment with 70% confidence.
Sentiment
Neutral
AI Confidence
70%
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND, held Decem
Original article published by
Unknown
on December 8, 2025.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.